Kyverna Therapeutics: Funding, Investors & Team (Oct 2026)
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Kyverna Therapeutics has raised $170M across 3 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Nov 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kyverna Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Kyverna Therapeutics Funding Rounds
Kyverna Therapeutics raised $85.0M in a Series B announced in Jan 2022.
1.6 years later, a Series B of $60.0M was announced in Aug 2023.
2.3 years later, an undisclosed round of $25.0M was announced in Nov 2025.
Kyverna Therapeutics Founders and Leadership Team
Contact details for the Kyverna Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Kyverna Therapeutics Funding Compared to Other Biotechnology Startups
Kyverna Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kyverna Therapeutics in Biotechnology and Berkeley
Companies Similar to Kyverna Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Kyverna Therapeutics Funding FAQs
What does Kyverna Therapeutics do?
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
How much funding has Kyverna Therapeutics raised?
Kyverna Therapeutics has raised $170M across 3 rounds on record. The most recent is an undisclosed round of $25.0M announced in Nov 2025.
When did Kyverna Therapeutics last raise funding?
Kyverna Therapeutics' most recent funding round on record is an undisclosed round of $25.0M, announced in Nov 2025.
Who founded Kyverna Therapeutics?
FundedIQ lists Jeffrey Greve (Founder) at Kyverna Therapeutics.
Who is the CEO of Kyverna Therapeutics?
Dominic Borie is listed as CEO at Kyverna Therapeutics.
Where is Kyverna Therapeutics headquartered?
Kyverna Therapeutics is based in Berkeley, California, United States.
How many employees does Kyverna Therapeutics have?
Kyverna Therapeutics is in the 11-50 employee band.
How does Kyverna Therapeutics' funding compare to other Biotechnology startups?
Kyverna Therapeutics' latest round of $25.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Kyverna Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kyverna Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.